At #ESMO25, AstraZeneca $AZN, Gilead $GILD square off in triple-negative breast cancer statnews.com/2025/10/19/esm… via Andrew Joseph

OptiTROP-Lung04 results NEJM after presentation from Li Zhang at #ESMO25. TROP2 ADC sac-TMT improves PFS and OS compared to standard platinum based chemotherapy in EGFR mutant NSCLC post TKI. A high bar has been set. #ESMOAmbassadors nejm.org/doi/full/10.10…

$SMMT will submit ivonescimab for FDA approval this quarter, based on the HARMONi results (EGFRm NSCLC) despite the lack of a stat sig OS benefit and against the recommendation of the FDA. smmttx.com/wp-content/upl…

FDA's podcast with Prasad: The new "plausible mechanism" drug approval pathway coming in 2 weeks -- to be published in NEJM open.spotify.com/episode/2J1YOk…

Cheers break out as Merck's Keytruda steals the show at ESMO #STATSummit statnews.com/2025/10/20/mer…

Tom is changing bladder cancer SOC, one ESMO - Eur. Oncology and ASCO meetings (twice/year) ….with concomitant NEJM publications! No surprise that Pr. Tom Powles is Top 10 nature people !

Two years ago, I received the Gilead Research Scholars Award. I’m delighted to provide updates on my work on drug tolerant persister cells in #lungcancer ESMO - Eur. Oncology. Sincerest gratitude to Gilead Sciences for their support! EGFR Resisters ALK Positive The ROS1ders, Inc. KRASKickers

Fantastic, thoughtful discussion between Oncology Brothers & Eric K. Singhi, MD about 1st line treatment options for #EGFR #NSCLC. Having options that have significant OS benefits is amazing, but all regimens have toxicities. Every lung #onc should not just prescribe treatment, but also

Honored to share my 🚀 SECOND simultaneous publication at #ESMO25 🚀, published in 📖 @AnnalsOfOncology 🎉 Our global leptomeningeal disease (#LMD) from #NSCLC cohort study (2,052 patients) sets benchmark outcomes for this rare population and generates hypotheses for

10 minutes to go ⏰ Join us LIVE as we break down the biggest #ESMO25 highlights in GI oncology 🎙️ With Tim Brown, MD MSCE, Udhayvir Grewal, and Nicholas Hornstein 👉 x.com/i/spaces/1BRJj… #ESMO25

Phenomenal (and sobering) review on treatment options in NSCLC post PD1. Crazy how nothing , even combos cannot beat docetaxel in 2nd line in large randomized P3s! PFS stuck on 4-5 months, OS HR ~0.85 at best. TROP2 ADCs were the latest casualties (both dato and Trodelvy) but it

Out on Lung Cancer Journal 👇 Despite overall poor prognosis, 13% of pts with #NSCLC and PS≥2 reached 5-year OS with IO mono (PD-L1 high setting) Out of ~40 variables, none alone explains it while AI reveals a complex, dynamic prognosis driven by more than disease-related factors

⚠️ Algorithm Updated: Updated the original Bladder Cancer Algorithm to improve visual flow. In the second algorithm, I tried incorporating updates from #ESMO2025 . Included KEYNOTE-905/EV-303, IMvigor011, RC48-C016 trials. #BladderCancer #OncTwitter ESMO - Eur. Oncology

It was a huge week for #BladderCancer at #ESMO25. Here are my takeaways from the most impactful trials pushing the field forward and improving patient care. 👇👇 DCI Center for Prostate & Urologic Cancers GU Oncology Now OncoDaily Bladder Cancer Advocacy Network LARVOL ESMO - Eur. Oncology

Great insights from Tony Mok Tony Mok and Solange Peters Solange Peters at the Global Lung Diagnostics Summit — spotlight on #EGFR BM and subgroups of interest in the evolving landscape of #LungCancer

Tripling up the Ph3 sample sizes is going to cost a lot of money! $SMMT

So, post conf season what are the biggest 2025 advances in thoracic cancers? For me #1 is T cell engager therapy (for now tarlatamab) in small cell lung cancer, #2 kras (largely based on data in panc), #3/hon mention neoadjuvant IO, old movie that keeps selling some seats! #lcsm